☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Otsuka
Otsuka and Astex Receive EC’s Approval for Inaqovi (decitabine and cedazuridine) to Treat Newly Diagnosed Acute Myeloid Leukaemia
September 19, 2023
Otsuka Entered into a Multi-Target Collaboration with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases
September 8, 2023
Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due...
May 12, 2023
Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis
May 4, 2023
Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophr...
April 27, 2023
Otsuka and Lundbeck Report the US FDA Acceptance of NDA for Aripiprazole to Treat Schizophrenia and Bipolar I Disorder
September 14, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.